Google and social networking enable news – both good and bad – to travel far and wide. Google Alerts have informed us that AVI’s stock has fallen below $1.00 and press releases talked about changes within the company. Amazing that we are all becoming experts on NASDAQ and stock prices!
Families participating in trials and others waiting for next exons and next steps, sit on the sidelines wondering and worrying.
I spoke with Chris Garabedian this morning (so reassuring to hear his voice) and our discussion confirmed AVI’s commitment to Duchenne.
For the record, drug development today is really difficult, perhaps the most difficult time ever. Investors are walking away and stock prices of small biotechs are trading at an all time low. But within that frame of reference, AVI intends to do everything to maintain their position on the NASDAQ. They are committed to Duchenne. Changes in the work force were done for efficiency and the desire to maintain the core team to move the Duchenne program. They look forward to un-blinding the DMD study in the second quarter of 2012 and with these results (cross fingers and pray), hope that the dataset will attract investors for their pivotal study.
Chris is fiercely protective of AVI and the Duchenne program and wishes all of you a wonderful holiday season.
Our community is strong. We are a family of believers. As you celebrate, please give thanks for all of the amazing people and companies who roll up their sleeves and do whatever necessary, whatever it takes to walk on this journey with us.
Pat Furlong, Founding President, CEO
Read more PPMD Staff Blogs